Ignite Creation Date:
2024-05-05 @ 12:00 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00203866
Status:
TERMINATED
Last Update Posted:
2013-09-05
First Post:
2005-09-12
Brief Title:
Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally AdvancedMetastatic Renal Cell Carcinoma
Sponsor:
University of Chicago
Organization:
University of Chicago
Study Overview
Official Title:
A Randomized Pilot Phase II Trial of Adjuvant Immunization With G250 Peptide andThree Different Dose Levels of IL-2 Following Surgical Resection of Locally Advanced or Metastatic Renal Cell Carcinoma
Status:
TERMINATED
Status Verified Date:
2013-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study completed
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether the experimental vaccine G250 with or without IL-2 can produce an immune response in patients with renal cell carcinoma who have had all their cancer removed by surgery
Detailed Description:
Renal cell carcinoma is a chemotherapy and radiotherapy resistant neoplasm that has a poor prognosis Immunotherapy with the biologic agent IL-2 consistently produces a response rate of 10-15 Currently for patients with locally advanced disease or patients with solitary metastases the only treatment modality with a curative potential is surgical resection There is presently no approved agent for use as adjuvant therapy after surgical resection to decrease the risk of recurrence Peptide-based vaccine approaches offer an attractive treatment option
The high prevalence of G250 in RCC the definition of an HLA-A2-restricted epitope the most common HLA type and its immunogenicity makes it the most attractive candidate for peptide-based vaccine approaches in RCC therapy The promising preclinical and clinical evidence provides the rationale for the use of IL-2 to potentiate the antitumor effects of cancer vaccines
There is presently no conclusive data on the best dose of IL-2 to use as an adjuvant to cancer vaccines One paradoxical finding in preclinical and clinical trials is that despite the enhancement in the antitumor effects of cancer vaccines the number of antigen-specific CTL is not increased when IL-2 is given with a cancer vaccine 35 In contrast patients treated with peptide vaccines without IL-2 in some melanoma trials had evidence of high levels of antigen-specific CTL with no tumor regression observed 36 Some possible explanations include capillary leak from high dose IL-2 resulting in CTL leaving the circulation and the possibility that high dose IL-2 decreases efficient T-cell priming A more recent explanation has been proposed through advances in the mechanism of 1-cell activation As their level of activation increases T-cells become more susceptible to apoptosis This phenomenon is known as activation-induced cell death AICD IL-2 may then have a role in the amplification and downregulation of the immune response High dose IL-2 may help in augmenting the increase in the activation of CTL but this may lead to increase their susceptibility to AJCD The evidence in animal models that low doses of IL-2 were sufficient in increasing the potency of DC-based immunizations provides the rational for our study
In our current study the lowest dose of IL-2 1 x 106 IU is similar to the doses used by Yee et al in their adoptive I cell therapy This dose has been shown to expand and maintain CTLs in both preclinical and clinical models The highest dose 11 x 106 IU was chosen based on the expected toxicities from higher doses of IL-2 and our experience with this dose as a single agent in RCC
Our hypothesis is that immunization with G250MontanideGM-CSF plus IL-2 can lead to an expansion of G250-specific CTL and result in killing of 0250 expressing micrometastatic RCC We propose a dose finding study of escalating low doses of IL 2 subcutaneous since no prior study has specifically evaluated the use of low dose IL-2 as a cytokine adjuvant and attempted to establish a correlation between dose and immunolgic response
The high prevalence of G250 in RCC the definition of an HLA-A2-restricted epitope the most common HLA type and its immunogenicity makes it the most attractive candidate for peptide-based vaccine approaches in RCC therapy The promising preclinical and clinical evidence provides the rationale for the use of IL-2 to potentiate the antitumor effects of cancer vaccines
There is presently no conclusive data on the best dose of IL-2 to use as an adjuvant to cancer vaccines One paradoxical finding in preclinical and clinical trials is that despite the enhancement in the antitumor effects of cancer vaccines the number of antigen-specific CTL is not increased when IL-2 is given with a cancer vaccine 35 In contrast patients treated with peptide vaccines without IL-2 in some melanoma trials had evidence of high levels of antigen-specific CTL with no tumor regression observed 36 Some possible explanations include capillary leak from high dose IL-2 resulting in CTL leaving the circulation and the possibility that high dose IL-2 decreases efficient T-cell priming A more recent explanation has been proposed through advances in the mechanism of 1-cell activation As their level of activation increases T-cells become more susceptible to apoptosis This phenomenon is known as activation-induced cell death AICD IL-2 may then have a role in the amplification and downregulation of the immune response High dose IL-2 may help in augmenting the increase in the activation of CTL but this may lead to increase their susceptibility to AJCD The evidence in animal models that low doses of IL-2 were sufficient in increasing the potency of DC-based immunizations provides the rational for our study
In our current study the lowest dose of IL-2 1 x 106 IU is similar to the doses used by Yee et al in their adoptive I cell therapy This dose has been shown to expand and maintain CTLs in both preclinical and clinical models The highest dose 11 x 106 IU was chosen based on the expected toxicities from higher doses of IL-2 and our experience with this dose as a single agent in RCC
Our hypothesis is that immunization with G250MontanideGM-CSF plus IL-2 can lead to an expansion of G250-specific CTL and result in killing of 0250 expressing micrometastatic RCC We propose a dose finding study of escalating low doses of IL 2 subcutaneous since no prior study has specifically evaluated the use of low dose IL-2 as a cytokine adjuvant and attempted to establish a correlation between dose and immunolgic response
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None